SG Americas Securities LLC Buys 4,666 Shares of AxoGen, Inc. (NASDAQ:AXGN)

SG Americas Securities LLC boosted its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 45.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,823 shares of the medical equipment provider’s stock after buying an additional 4,666 shares during the quarter. SG Americas Securities LLC’s holdings in AxoGen were worth $101,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tocqueville Asset Management L.P. raised its stake in shares of AxoGen by 98.7% during the third quarter. Tocqueville Asset Management L.P. now owns 934,900 shares of the medical equipment provider’s stock valued at $4,674,000 after acquiring an additional 464,500 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of AxoGen by 24.1% in the 3rd quarter. Acadian Asset Management LLC now owns 178,989 shares of the medical equipment provider’s stock worth $893,000 after buying an additional 34,797 shares during the period. Barclays PLC grew its position in shares of AxoGen by 18.1% during the 3rd quarter. Barclays PLC now owns 28,655 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 4,387 shares in the last quarter. M&T Bank Corp increased its stake in shares of AxoGen by 28.7% during the third quarter. M&T Bank Corp now owns 48,036 shares of the medical equipment provider’s stock valued at $240,000 after buying an additional 10,698 shares during the period. Finally, Panagora Asset Management Inc. raised its holdings in shares of AxoGen by 171.6% in the third quarter. Panagora Asset Management Inc. now owns 97,460 shares of the medical equipment provider’s stock valued at $487,000 after acquiring an additional 61,578 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on AXGN shares. Cantor Fitzgerald reissued an “overweight” rating and set a $12.00 target price on shares of AxoGen in a research report on Friday, January 19th. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th.

Insider Buying and Selling at AxoGen

In other news, VP Michael Patrick Donovan sold 36,310 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $8.81, for a total transaction of $319,891.10. Following the transaction, the vice president now directly owns 35,708 shares of the company’s stock, valued at $314,587.48. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, VP Michael Patrick Donovan sold 36,310 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $8.81, for a total transaction of $319,891.10. Following the sale, the vice president now owns 35,708 shares in the company, valued at $314,587.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Karen L. Zaderej sold 39,280 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $7.68, for a total transaction of $301,670.40. Following the transaction, the chief executive officer now owns 1,124,565 shares in the company, valued at approximately $8,636,659.20. The disclosure for this sale can be found here. Insiders sold a total of 111,201 shares of company stock worth $928,054 over the last three months. Corporate insiders own 7.21% of the company’s stock.

AxoGen Price Performance

AXGN opened at $6.50 on Friday. The firm has a market capitalization of $283.97 million, a PE ratio of -12.50 and a beta of 1.03. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.89 and a quick ratio of 2.14. The business’s 50-day moving average is $8.61 and its two-hundred day moving average is $7.29. AxoGen, Inc. has a 1 year low of $3.45 and a 1 year high of $10.83.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.11. The business had revenue of $42.92 million for the quarter, compared to analysts’ expectations of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative return on equity of 22.38%. Research analysts anticipate that AxoGen, Inc. will post -0.46 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.